Skip to main content
Equibles
ENGN logo

ENGN · enGene Therapeutics Inc.

Track ENGN — free

Use ENGN with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$1.82 -0.01 (-0.55%) At close · Sep 4
Rebalance outlook locked
Going-concern doubt — cleared Jun 15, 2026

The latest filing states the doubt was alleviated.

“In accordance with Accounting Standards Codification ("ASC") 205-40, Going Concern, the Company has evaluated whether there are any conditions and events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern within one year after the date these consolidated financial statements are issued. As of the issuance date of these consolidated financial statements, the Company expects that its existing cash, cash equivalents and marketable securities as of April 30, 2026 will be sufficient to fund its operating expenses and debt obligations requirements for at least the next 12 months.”
View the 10-Q filed Jun 15, 2026
Market Cap
$126.61M
Shares
66.99M

ENGN metrics

54 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$1.82
Market cap
$126.61M

Price action

19 metrics
Price change (1W)
-0.3%
Price change (30D)
+1.1%
Price change (3M)
+11.0%
Price change (6M)
-79.0%
Price change (YTD)
-79.8%
Price change (1Y)
-63.6%
Trailing year
Price change (5Y)
—
52-week high
$12.17
52-week low
$1.44
Change from 52-week high
-85.0%
Change from 52-week low
+26.4%
Annualized volatility
121.8%
Beta
2.2
RSI (14D)
49.0
Price vs SMA 50
+0.0%
Price vs SMA 200
-67.7%
Avg volume (3M)
872,396
Relative volume
0.5
Average dollar volume
$1.57M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
66.99M

Valuation

12 metrics
P / E (TTM)
0.8
Trailing earnings · reciprocal yield 128.0%
PEG ratio
0.0
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.5
reciprocal yield 201.5%
FCF yield
-88.0%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-100.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$132.58M
Net income (TTM)
−$126.85M
Trailing 12 months
Diluted EPS (TTM)
$2.33
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-115.08

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
+56.8%
Shares change YoY
+36.7%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
-62.7%
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-49.7%
Return on assets
-41.2%
Debt / equity
—
Current ratio
12.6
EBITDA (TTM)
—
Free cash flow (TTM)
−$111.39M
Quick ratio
12.6
Interest coverage
-44.4
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$258.46M
Latest balance sheet
Cash & equivalents
$29.83M
Total assets
$307.52M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$110.00M
Capital expenditures (TTM)
$1.39M
R&D (TTM)
$98.75M
SG&A (TTM)
—
Stock compensation (TTM)
$12.13M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
70
13F filer change QoQ
+9
Institutional ownership
79.2%

Short interest

3 metrics
Short interest
2.2%
Latest settlement · 2.2 days to cover
Days to cover
2.2d
Short-squeeze score
46 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1980845 CUSIP 29286X101 13F (30d) 55 filings 55 filers Visit website